StockData

NanoViricides, Inc. (NNVC) stock

NNVCNYSEPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$1.19+0.03 (+2.59%)

Close on Nov 18, 2026Market cap $30.37MP/E –Yield –

NanoViricides operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

NanoViricides's operating income for the twelve months ending Jun 30, 2026 was -$8.31M. For fiscal 2026 it was -$8.31M. The highest annual figure on record is -$4.94M in fiscal 2010.

Annual operating income

PeriodPeriod endValueChange
FY2026Jun 30, 2026-$8.31M–
FY2025Jun 30, 2025-$9.59M–
FY2024Jun 30, 2024-$8.52M–
FY2023Jun 30, 2023-$8.94M–
FY2022Jun 30, 2022-$8.11M–
FY2021Jun 30, 2021-$8.74M–
FY2020Jun 30, 2020-$8.00M–
FY2019Jun 30, 2019-$8.66M–
FY2018Jun 30, 2018-$9.33M–
FY2017Jun 30, 2017-$9.60M–
FY2016Jun 30, 2016-$8.86M–
FY2015Jun 30, 2015-$7.06M–
FY2014Jun 30, 2014-$8.67M–
FY2013Jun 30, 2013-$6.59M–
FY2012Jun 30, 2012-$6.08M–
FY2011Jun 30, 2011-$6.43M–
FY2010Jun 30, 2010-$4.94M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ2 2026Jun 30, 2026-$2.25M–
Q3 FY2026CQ1 2026Mar 31, 2026-$2.03M–
Q2 FY2026CQ4 2025Dec 31, 2025-$2.23M–
Q1 FY2026CQ3 2025Sep 30, 2025-$1.80M–
Q4 FY2025CQ2 2025Jun 30, 2025-$2.12M–
Q3 FY2025CQ1 2025Mar 31, 2025-$2.25M–
Q2 FY2025CQ4 2024Dec 31, 2024-$2.06M–
Q1 FY2025CQ3 2024Sep 30, 2024-$3.17M–
Q4 FY2024CQ2 2024Jun 30, 2024-$2.39M–
Q3 FY2024CQ1 2024Mar 31, 2024-$1.91M–
Q2 FY2024CQ4 2023Dec 31, 2023-$2.18M–
Q1 FY2024CQ3 2023Sep 30, 2023-$2.03M–
Q4 FY2023CQ2 2023Jun 30, 2023-$3.68M–
Q3 FY2023CQ1 2023Mar 31, 2023-$1.81M–
Q2 FY2023CQ4 2022Dec 31, 2022-$1.83M–
Q1 FY2023CQ3 2022Sep 30, 2022-$1.62M–
Q4 FY2022CQ2 2022Jun 30, 2022-$1.79M–
Q3 FY2022CQ1 2022Mar 31, 2022-$1.79M–
Q2 FY2022CQ4 2021Dec 31, 2021-$1.92M–
Q1 FY2022CQ3 2021Sep 30, 2021-$2.61M–
Q4 FY2021CQ2 2021Jun 30, 2021-$2.07M–
Q3 FY2021CQ1 2021Mar 31, 2021-$2.11M–
Q2 FY2021CQ4 2020Dec 31, 2020-$2.29M–
Q1 FY2021CQ3 2020Sep 30, 2020-$2.27M–
Q4 FY2020CQ2 2020Jun 30, 2020-$1.83M–
Q3 FY2020CQ1 2020Mar 31, 2020-$2.54M–
Q2 FY2020CQ4 2019Dec 31, 2019-$1.63M–
Q1 FY2020CQ3 2019Sep 30, 2019-$1.99M–
Q4 FY2019CQ2 2019Jun 30, 2019-$2.17M–
Q3 FY2019CQ1 2019Mar 31, 2019-$2.08M–
Q2 FY2019CQ4 2018Dec 31, 2018-$2.37M–
Q1 FY2019CQ3 2018Sep 30, 2018-$2.04M–
Q4 FY2018CQ2 2018Jun 30, 2018-$2.28M–
Q3 FY2018CQ1 2018Mar 31, 2018-$2.42M–
Q2 FY2018CQ4 2017Dec 31, 2017-$2.39M–
Q1 FY2018CQ3 2017Sep 30, 2017-$2.23M–
Q4 FY2017CQ2 2017Jun 30, 2017-$2.25M–
Q3 FY2017CQ1 2017Mar 31, 2017-$2.62M–
Q2 FY2017CQ4 2016Dec 31, 2016-$2.30M–
Q1 FY2017CQ3 2016Sep 30, 2016-$2.44M–

More NanoViricides figures

See a number that looks wrong?